JP7086171B2 - 共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法 - Google Patents

共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法 Download PDF

Info

Publication number
JP7086171B2
JP7086171B2 JP2020504290A JP2020504290A JP7086171B2 JP 7086171 B2 JP7086171 B2 JP 7086171B2 JP 2020504290 A JP2020504290 A JP 2020504290A JP 2020504290 A JP2020504290 A JP 2020504290A JP 7086171 B2 JP7086171 B2 JP 7086171B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
cycloalkyl
heteroaryl
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516679A5 (cg-RX-API-DMAC7.html
JP2020516679A (ja
Inventor
シャオメン ワン
ジェーン スタッキー
リュー リュー
ジャンフェン ロ
ハイビン チョウ
リャンヨウ ルイ
イー スン
Original Assignee
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Publication of JP2020516679A publication Critical patent/JP2020516679A/ja
Publication of JP2020516679A5 publication Critical patent/JP2020516679A5/ja
Application granted granted Critical
Publication of JP7086171B2 publication Critical patent/JP7086171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020504290A 2017-04-10 2018-04-10 共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法 Active JP7086171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483640P 2017-04-10 2017-04-10
US62/483,640 2017-04-10
PCT/US2018/026789 WO2018191199A1 (en) 2017-04-10 2018-04-10 Covalent small molecule dcn1 inhibitors and therapeutic methods using the same

Publications (3)

Publication Number Publication Date
JP2020516679A JP2020516679A (ja) 2020-06-11
JP2020516679A5 JP2020516679A5 (cg-RX-API-DMAC7.html) 2021-04-15
JP7086171B2 true JP7086171B2 (ja) 2022-06-17

Family

ID=62067873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504290A Active JP7086171B2 (ja) 2017-04-10 2018-04-10 共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法

Country Status (8)

Country Link
US (1) US10500194B2 (cg-RX-API-DMAC7.html)
EP (1) EP3609876B1 (cg-RX-API-DMAC7.html)
JP (1) JP7086171B2 (cg-RX-API-DMAC7.html)
CN (1) CN110740996B (cg-RX-API-DMAC7.html)
AU (1) AU2018251687B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059256C (cg-RX-API-DMAC7.html)
ES (1) ES2916449T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018191199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
EP3883597A2 (en) * 2018-11-20 2021-09-29 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
EP3938050A1 (en) 2019-03-15 2022-01-19 Fulcrum Therapeutics, Inc. Macrocyclic azolopyridine derivatives as eed and prc2 modulators
AU2021397774A1 (en) * 2020-12-10 2023-06-29 Adgero Biopharmaceuticals Holdings, Inc. Methods for treating cutaneous metastatic cancers
CN112830957B (zh) * 2021-01-07 2022-07-22 江西师范大学 一种制备卡非佐米的方法
WO2023059605A1 (en) * 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
WO2023059582A1 (en) * 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
AU2023283735A1 (en) 2022-06-06 2024-10-31 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
CN116987062A (zh) * 2023-08-03 2023-11-03 中国热带农业科学院分析测试中心 一种氨基酸键联槟榔碱衍生物的制备方法
WO2025096956A1 (en) 2023-11-03 2025-05-08 Cellarity, Inc. Dcn-1 modulating compounds and methods of use thereof
WO2025096981A1 (en) 2023-11-03 2025-05-08 Cellarity, Inc. Modulators of dcn-1 and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049295A1 (en) 2015-09-18 2017-03-23 St. Jude Children's Research Hospital Methods and compositions of inhibiting dcn1-ubc12 interaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234264A (en) * 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049295A1 (en) 2015-09-18 2017-03-23 St. Jude Children's Research Hospital Methods and compositions of inhibiting dcn1-ubc12 interaction

Also Published As

Publication number Publication date
ES2916449T3 (es) 2022-07-01
US10500194B2 (en) 2019-12-10
CA3059256A1 (en) 2018-10-18
US20180289677A1 (en) 2018-10-11
EP3609876B1 (en) 2022-03-30
JP2020516679A (ja) 2020-06-11
CA3059256C (en) 2024-04-16
CN110740996A (zh) 2020-01-31
CN110740996B (zh) 2024-01-09
AU2018251687A1 (en) 2019-10-24
EP3609876A1 (en) 2020-02-19
WO2018191199A1 (en) 2018-10-18
AU2018251687B2 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7086171B2 (ja) 共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法
US12012467B2 (en) Small molecule DCN1 inhibitors and therapeutic methods using the same
JP7394074B2 (ja) 治療用化合物
JP6873980B2 (ja) ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
US9233086B2 (en) Inhibition of WDR5 interaction with its binding partners
EP2888265B1 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
JP6537532B2 (ja) 補体媒介障害の治療のための化合物
CN114867735A (zh) Ras抑制剂
US10308662B2 (en) Thienopyranones as kinase and epigenetic inhibitors
JP4523073B2 (ja) 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
CN110291084A (zh) 用于治疗癌症的组合物和方法
CN106413716A (zh) 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
WO2018236971A1 (en) Single molecule compounds providing multi-target inhibition of parp and other proteins and methods of use thereof
US8980838B2 (en) Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction
EP1899346B1 (en) Pyrrolotriazine compounds useful as kinase inhibitors
US20210300939A1 (en) Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof
EP2651949B1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
WO2023220722A2 (en) Pak1 degraders and methods of use thereof
HK40076319A (en) Ras inhibitors
HK40013658A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220607

R150 Certificate of patent or registration of utility model

Ref document number: 7086171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250